Back to Search
Start Over
Comparison of efficacy, safety, patients’ quality of life, and doctors’ occupational stress between lenalidomide‐based and bortezomib‐based induction in patients with newly diagnosed multiple myeloma
- Source :
- Cancer Medicine, Vol 10, Iss 5, Pp 1656-1667 (2021), Cancer Medicine
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Background In the new therapeutic era, comparisons between regimens containing lenalidomide and bortezomib are needed. Methods In this single‐center, prospective study, patients received four to six cycles of lenalidomide+liposomal doxorubicin+dexamethasone (RAD) or bortezomib+liposomal doxorubicin+dexamethasone (PAD) every 4 weeks, with subsequent autologous stem cell transplantation (ASCT) and maintenance therapy. We compared the efficacy, safety, patients’ quality of life, and doctors’ occupational stress between RAD and PAD induction in newly diagnosed MM patients. Results The complete response (CR) rate was comparable between the RAD and PAD groups after induction (30.8% vs. 32.0%, p = 0.92). Common adverse events, including infections, peripheral neuropathy, and gastrointestinal disturbances, were more frequent in the PAD group, while leukopenia and rashes were more common in the RAD group. Compared with PAD, RAD improved patients’ quality of life more quickly and caused less occupational stress for doctors. However, only 31.6% of patients collected adequate CD34+ cells (≥2 × 106/kg) in the RAD group, which was significantly lower than that in the PAD group (95.5%, p<br />Compared to PAD, RAD induction had a comparable efficacy and significantly better safety profile, improved quality of life for patients and reduced occupational stress for doctors. However, RAD had an effect on stem cell collection, which may need to be limited to 4 cycles to avoid irreversible damage to hematopoietic stem cells.
- Subjects :
- Male
0301 basic medicine
Oncology
Cancer Research
Dexamethasone
Polyethylene Glycols
0302 clinical medicine
Autologous stem-cell transplantation
Maintenance therapy
Antineoplastic Combined Chemotherapy Protocols
Medical Staff
Prospective Studies
Multiple myeloma
RC254-282
Original Research
Leukopenia
Bortezomib
bortezomib
Hematopoietic Stem Cell Transplantation
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Induction Chemotherapy
Middle Aged
Combined Modality Therapy
Hematopoietic Stem Cell Mobilization
Progression-Free Survival
Treatment Outcome
030220 oncology & carcinogenesis
Female
Safety
medicine.symptom
Multiple Myeloma
medicine.drug
Adult
medicine.medical_specialty
lenalidomide
Transplantation, Autologous
Drug Administration Schedule
stem cell collection
Maintenance Chemotherapy
03 medical and health sciences
Internal medicine
medicine
Humans
Radiology, Nuclear Medicine and imaging
Propensity Score
Adverse effect
Aged
Lenalidomide
business.industry
Clinical Cancer Research
medicine.disease
030104 developmental biology
quality of life
Doxorubicin
Nursing Staff
business
occupational stress
Subjects
Details
- Language :
- English
- ISSN :
- 20457634
- Volume :
- 10
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Cancer Medicine
- Accession number :
- edsair.doi.dedup.....b99d2baf639f4f07e585c409a3785c9a